Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R H Böger

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Deutsche Medizinische Wochenschrift (1946)|April 1, 2004
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data]R H Böger
Deutsche Medizinische Wochenschrift (1946)|August 23, 2002
[How would chronic heart insufficiency actually be treated today?]R H Böger
International Journal of Clinical Pharmacology and Therapeutics|September 21, 2001
Drug interactions of the statins and consequences for drug selectionR H Böger
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|September 16, 2000
Role of nitric oxide in the haemodynamic effects of growth hormoneR H Böger
Journal of Endocrinological Investigation|August 12, 1999
Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humansR H Böger
Der Internist|June 11, 2002
[End points of clinical studies: surrogate parameters of "hard clinical end points"?]R H Böger
Zeitschrift Fur Kardiologie|February 28, 2001
[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options]K Sydow, R H Böger
International Journal of Clinical Pharmacology and Therapeutics|September 6, 2011
A survey on clinical study participation and study infrastructure at non-university hospitals in GermanyO Heese, R H Böger, M Westphal
Annual Review of Pharmacology and Toxicology|March 27, 2001
The clinical pharmacology of L-arginineR H Böger, S M Bode-Böger
Seminars in Thrombosis and Hemostasis|December 29, 2000
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseasesR H Böger, S M Bode-Böger
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Deutsche Medizinische Wochenschrift (1946)|April 1, 2004
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data]R H Böger
Deutsche Medizinische Wochenschrift (1946)|August 23, 2002
[How would chronic heart insufficiency actually be treated today?]R H Böger
International Journal of Clinical Pharmacology and Therapeutics|September 21, 2001
Drug interactions of the statins and consequences for drug selectionR H Böger
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|September 16, 2000
Role of nitric oxide in the haemodynamic effects of growth hormoneR H Böger
Journal of Endocrinological Investigation|August 12, 1999
Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humansR H Böger
Der Internist|June 11, 2002
[End points of clinical studies: surrogate parameters of "hard clinical end points"?]R H Böger
Zeitschrift Fur Kardiologie|February 28, 2001
[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options]K Sydow, R H Böger
International Journal of Clinical Pharmacology and Therapeutics|September 6, 2011
A survey on clinical study participation and study infrastructure at non-university hospitals in GermanyO Heese, R H Böger, M Westphal
Annual Review of Pharmacology and Toxicology|March 27, 2001
The clinical pharmacology of L-arginineR H Böger, S M Bode-Böger
Seminars in Thrombosis and Hemostasis|December 29, 2000
Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseasesR H Böger, S M Bode-Böger
Pageof 8